Zoetis Inc. (NYSE:ZTS) has been given a $75.00 price objective by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 24.51% from the company’s current price. Cantor Fitzgerald also issued estimates for Zoetis’ FY2017 earnings at $2.30 EPS.

Several other analysts also recently weighed in on ZTS. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $62.00 price objective on shares of Zoetis in a research report on Monday, August 7th. Deutsche Bank AG cut shares of Zoetis from a “buy” rating to a “hold” rating and set a $65.00 price objective on the stock. in a research note on Tuesday, July 25th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research note on Friday, July 21st. Cowen and Company set a $70.00 price objective on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Finally, Zacks Investment Research cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company. Zoetis has an average rating of “Buy” and a consensus price target of $64.78.

Zoetis (ZTS) traded up 1.69% during midday trading on Monday, hitting $60.74. 1,091,038 shares of the stock traded hands. The company has a market cap of $29.71 billion, a PE ratio of 34.34 and a beta of 1.02. Zoetis has a one year low of $46.86 and a one year high of $63.85. The company’s 50-day moving average is $62.20 and its 200-day moving average is $58.00.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the business earned $0.49 EPS. Equities research analysts expect that Zoetis will post $2.34 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/cantor-fitzgerald-analysts-give-zoetis-inc-nysezts-a-75-00-price-target/1487218.html.

Large investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock valued at $1,925,722,000 after buying an additional 34,679,064 shares during the last quarter. Morgan Stanley boosted its position in shares of Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after buying an additional 9,442,207 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Zoetis during the first quarter worth approximately $243,854,000. Alliancebernstein L.P. boosted its position in shares of Zoetis by 55.4% in the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after buying an additional 3,695,449 shares during the last quarter. Finally, Waddell & Reed Financial Inc. boosted its position in shares of Zoetis by 65.9% in the first quarter. Waddell & Reed Financial Inc. now owns 5,434,371 shares of the company’s stock worth $290,033,000 after buying an additional 2,157,803 shares during the last quarter. 92.70% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.